Has Walter Trombold received payments from drug or device companies?

Yes. Drug and device makers reported $2,921 in general payments to Walter Trombold across 177 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Walter Trombold did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Walter Trombold come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Walter Trombold

Pulmonary Disease · Springfield, MONPI 1023027281

Payments from drug & device makers

$2,921in general payments, 2019–2025

Across 177 payments — averaging $16.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

GSK$445
AstraZeneca$382
United Therapeutics Corporation$315
Boehringer Ingelheim$179
Mylan Specialty L.p.$156
Genentech USA, Inc.$156
plus $1K from 22 others

What the payments were for

Food & beverage$2,90199%
Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
GSK	37	$445
AstraZeneca	19	$382
United Therapeutics Corporation	13	$315
Boehringer Ingelheim	14	$179
Mylan Specialty L.p.	11	$156
Genentech USA, Inc.	10	$156
Actelion Pharmaceuticals US, Inc.	8	$140
Novartis	7	$137
Pfizer	8	$118
Grifols USA, LLC	5	$95
CSL Behring	5	$95
AbbVie	4	$82
Circassia Inc.	5	$80
Merck	4	$78
Regeneron Healthcare Solutions, Inc.	3	$57
Mallinckrodt Hospital Products Inc.	3	$55
ANI Pharmaceuticals, Inc.	2	$41
Philips North America LLC	2	$40
Amgen	2	$38
Johnson & Johnson	2	$36
Insmed, Inc.	2	$35
Idorsia Pharmaceuticals US Inc	2	$34
Astellas Pharma US Inc	2	$32
Sunovion Pharmaceuticals Inc.	2	$25
Jazz Pharmaceuticals Inc.	1	$22
Electromed, Inc.	2	$20
Pulmonx Corporation	1	$13
Teva Pharmaceuticals USA, Inc.	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,921 in reported general payments places this provider in the 55th percentile of 295 pulmonary disease providers in Missouri.

See all pulmonary disease providers in Missouri →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
OpsumitMacitentan	46	$584,450
AdempasRiociguat	13	$177,061
Ambrisentan	31	$53,877
Tadalafil	33	$25,947
Trelegy ElliptaFluticasone/Umeclidin/Vilanter	18	$16,885
Breztri AerosphereBudesonide/Glycopyr/Formoterol	23	$14,263
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate	12	$1,748
Azithromycin	59	$899
Albuterol Sulfate HfaAlbuterol Sulfate	17	$501
Famotidine	20	$169
Pantoprazole Sodium	11	$93
Omeprazole	12	$78
Furosemide	13	$57
Spironolactone	12	$27

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit	$140	$584,45046 claims
GSKTrelegy Ellipta	$445	$16,88518 claims
AstraZenecaBreztri Aerosphere	$382	$14,26323 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 295 pulmonary disease providers in Missouri.

Other pulmonary disease in Springfield

Madhu Kalyan PendurthiSpringfield$470K
Steven HullLees Summit$10.1M
Thomas SilerSaint Charles$5.5M
Neil EttingerChesterfield$3.5M
Humam FarahHannibal$2.7M
Murali ChakinalaSaint Louis$2.4M
Joseph OjileSaint Louis$2.1M
Jeffrey HarrisSaint Louis$1.1M
Kaharu SuminoSaint Louis$1.1M
Tonya RussellSaint Louis$1M

See the full list for Missouri →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →